Exploring the Pharmacokinetic Profile of Antiretroviral Efavirenz in Low Protein Malnourished Condition in Wistar Rats [0.03%]
探讨抗逆转录病毒药物依非韦伦在蛋白质缺乏型营养不良状况下的药动学特征：大鼠实验研究
Sachin V Tembhurne,Swarupa V Sul,Shubham N Gavade et al.
Sachin V Tembhurne et al.
Background and objectives: The HIV infection in malnourished conditions raises the concerns with antiretroviral medications, which may worsen the already compromised physiological state. The alteration in the plasma prote...
Tacrolimus Trough Concentrations are Not Impacted by Epstein-Barr Virus Serology and Viral Load in Pediatric Liver Transplant Recipients [0.03%]
他克莫司谷浓度不受爱泼斯坦-巴尔病毒血清学和病毒载量在儿童肝移植受者中的影响
Amber M Te Lintelo,Lisa F van Wier,Hubert P J van der Doef et al.
Amber M Te Lintelo et al.
Background and objectives: Epstein-Barr virus (EBV) is a common herpesvirus among pediatric liver transplant recipients, but it can have serious complications, such as post-transplant lymphoproliferative disease. EBV is h...
Dose, Kidney Function, and a Drug-Excipient Interaction Impair Mycophenolate Mofetil Prodrug Activation in Kidney Transplant Recipients [0.03%]
他克莫司剂量、肾功能与药物辅料相互作用影响肾脏移植受者的霉酚酸酯前药活化
Fleur B Nijdam,Marieke A J Hof,Daan Kremer et al.
Fleur B Nijdam et al.
Background and objective: Current immunosuppressive treatment to prevent graft rejection in organ transplant recipients commonly includes mycophenolate mofetil (MMF) and a calcineurin inhibitor. After absorption, MMF is a...
Xiaomeng Pan,Dandan Li,Yujuan Chen et al.
Xiaomeng Pan et al.
Background and objective: Hyperuricemia (HUA) is a metabolic disease closely associated with hypertension. It can induce liver damage, subsequently affecting drug metabolism. However, its specific impacts and underlying m...
Regulation for the Bioequivalence Evaluation of Generic Topical Dermatological Drug Products in Japan [0.03%]
日本仿制外用皮肤病药物生物等效性评价的监管要求
Miho Kasuga,Kimika Kuwana,Ryosuke Kuribayashi
Miho Kasuga
Background and objective: In Japan, the "Guideline for Bioequivalence (BE) Studies of Generic Products for Topical Use" was issued in 2003 to present the basic principles for BE evaluation methods for generic topical derm...
Bioequivalence and Safety of Bilastine 20 mg Administered in Three Eight-Hourly Dose Versus a Single Daily Dose: A Randomized Two-Treatment, Two-Period, Cross-Over Comparative Study [0.03%]
比来司亭20毫克八小时给药三次与每日一次给药的生物等效性和安全性：一项随机两制剂、两周期交叉对比研究
Ekta Sinha,Sagar Bhagat,Saiprasad Patil et al.
Ekta Sinha et al.
Background and objective: Antihistamines are an essential treatment option for cough and upper respiratory symptoms. Bilastine is a 2nd-generation antihistamine which is approved as a 20 mg once daily dose. The objective ...
Pharmacokinetic Characterization of Cendakimab Administered with Different Devices and at Different Injection Sites in Healthy Participants [0.03%]
在健康受试者中通过不同装置和注射部位给药的Cendakimab的药代动力学特征研究
Peijin Zhang,Claudia H M C De Oliveira,Kyungha Yu et al.
Peijin Zhang et al.
Background and objective: The cendakimab (CC-93538, previously RPC4046) phase 3 trial used prefilled syringes (PFS), while the intended commercial product is an autoinjector (AI). This study evaluated the pharmacokinetic ...
Pharmacokinetics of Intraperitoneal Lidocaine for Sustained Postoperative Analgesia in Adults [0.03%]
成人腹腔内利多卡因的药代动力学用于术后镇痛
Kenyon W Osborne,Wiremu S MacFater,Brian J Anderson et al.
Kenyon W Osborne et al.
Background and objective: Intraperitoneal lidocaine is an emerging strategy for analgesia following abdominal surgery but its pharmacokinetics are poorly quantified. We aimed to develop a pharmacokinetic model for unbound...
Clinical Pharmacokinetics and Pharmacodynamics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor [0.03%]
口服低氧诱导因子脯氨酰羟化酶抑制剂 vadadustat 的临床药动学和药效学研究
Slobodan M Janković,Snežana V Janković
Slobodan M Janković
Vadadustat is an innovative drug that inhibits prolyl hydroxylase and has been approved for the treatment of anemia in patients with chronic kidney disease. Its pharmacokinetics are linear, i.e., vadadustat's absorption, distribution, and e...
Host Biomarkers and Antibiotic Tissue Penetration in Sepsis: Insights from Moxifloxacin [0.03%]
宿主生物标志物和抗生素组织渗透在脓毒症中的作用：来自莫西沙星的见解
Maria Sanz-Codina,Hartmuth Nowak,Markus Zeitlinger
Maria Sanz-Codina
Background and objective: Sepsis-induced pathophysiological changes may lead to pharmacokinetic variability which alters antibiotic concentrations at the host infection site. This poses a challenge in clinical practice, a...